
Artivion (AORT) Stock Forecast & Price Target
Artivion (AORT) Analyst Ratings
Bulls say
Artivion is in a strong financial position with a solid revenue growth rate of 8-12% driven by new product launches and international expansion. However, one risk is the delay in clinical trials or new product approvals, which could impact the company's revenue growth. Another risk is worse than expected stent graft sales, which could also hinder revenue growth. Despite these risks, the company has a strong pipeline and product portfolio that positions it for potential upside in the future, supporting a positive outlook.
Bears say
Artivion is a medical device company with a negative outlook, as their recent quarterly results indicated a top-line beat but lowered revenue and EBITDA guidance for the full year. Their bear case scenario predicts a share price of $18, based on a 2027 sales estimate of 2.0x EV/sales. While the company has potential for long-term growth, with opportunities for new product launches and expansion into international markets, there are concerns about delays and potential issues with suppliers. Additionally, the company's use of free cash flow for future earn-outs and debt repayment may limit potential returns for investors.
This aggregate rating is based on analysts' research of Artivion and is not a guaranteed prediction by Public.com or investment advice.
Artivion (AORT) Analyst Forecast & Price Prediction
Start investing in Artivion (AORT)
Order type
Buy in
Order amount
Est. shares
0 shares